Posted by Michael Wonder on 25 Sep 2017
First-in-class BRCA-positive ovarian cancer medicine Lynparza (olaparib) receives positive pan-Canadian Oncology Drug Review recommendation for provincial reimbursement
21 September 2017 - This marks an important first step towards providing Canadian women with access to this treatment.
AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug Review (pCODR) has provided an overwhelmingly positive clinical recommendation for the reimbursement of Lynparza (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer. Lynparza is an oral, potent inhibitor of poly (ADP-ribose) polymerase (PARP) available as a maintenance treatment for patients with platinum-sensitive relapsed BRCA-mutated ovarian cancer. Strong clinical data shows improved progression-free survival among patients, as well as significant reduction in disease progression (70%).
AstraZeneca applauds the decision, noting that this comes as a reflection of the strong clinical evidence that supports the benefits of Lynparza for use in a well-defined subset of ovarian cancer patients.
